10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q3 2017

Filing Information

Form Type	10-Q
Accession Number	`0001532176-17-000034`
Period End Date	20170930
Filing Date	20171108
Fiscal Year	2017
Fiscal Period	Q3
XBRL Instance	regn-20170930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 100 Cash Flow Statement 58

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$792.07M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$920.36M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$586.88M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$503.48M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.34B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.53B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$217.48M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$92.99M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$221.28M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$175.26M	USD	Point-in-time
Inventories	`InventoryNet`	$399.36M	USD	Point-in-time
Inventories	`InventoryNet`	$641.59M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$143.76M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$130.53M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.18B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.14B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.33B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$864.26M	USD	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Property, Plant, and Equipment, Net	`PropertyPlantAndEquipmentNet`	$2.08B	USD	Point-in-time
Property, Plant, and Equipment, Net	`PropertyPlantAndEquipmentNet`	$2.27B	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$825.30M	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$927.02M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$20.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$36.62M	USD	Point-in-time
Total assets	`Assets`	$8.70B	USD	Point-in-time
Total assets	`Assets`	$6.97B	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$879.10M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$818.43M	USD	Point-in-time
Capital and facility lease obligations, current	`Capitalandfacilityleaseobligationscurrent`	-	USD	Point-in-time
Capital and facility lease obligations, current	`Capitalandfacilityleaseobligationscurrent`	$129.56M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$187.04M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$115.27M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$116.40M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$132.83M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.18M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$334.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.24B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.14B	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$702.32M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$351.57M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$503.47M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$408.79M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$274.67M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$327.30M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$100.39M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$125.22M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.65B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.52B	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.03B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.57B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.77B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.75B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$23.84M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-12.84M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.05B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.45B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$6.97B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$8.70B	USD	Point-in-time

Income Statement 100 line items

Line Item	Tag	Value	Unit	Period
Net product sales	`SalesRevenueGoodsNet`	$957.37M	USD	1 Quarter
Net product sales	`SalesRevenueGoodsNet`	$857.47M	USD	1 Quarter
Net product sales	`SalesRevenueGoodsNet`	$2.74B	USD	3 Qtrs
Net product sales	`SalesRevenueGoodsNet`	$2.48B	USD	3 Qtrs
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$677.67M	USD	3 Qtrs
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$245.18M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$527.50M	USD	3 Qtrs
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$144.39M	USD	1 Quarter
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$640.92M	USD	3 Qtrs
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$562.79M	USD	3 Qtrs
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$236.62M	USD	1 Quarter
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$191.30M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$231.45M	USD	3 Qtrs
Other revenue	`OtherSalesRevenueNet`	$67.44M	USD	3 Qtrs
Other revenue	`OtherSalesRevenueNet`	$26.96M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$61.51M	USD	1 Quarter
Total revenues	`Revenues`	$4.29B	USD	3 Qtrs
Total revenues	`Revenues`	$1.50B	USD	1 Quarter
Total revenues	`Revenues`	$1.22B	USD	1 Quarter
Total revenues	`Revenues`	$3.63B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$529.75M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$543.05M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.57B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.55B	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$306.77M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$270.05M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$910.52M	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$851.76M	USD	3 Qtrs
Cost of goods sold	`CostOfGoodsSold`	$150.09M	USD	3 Qtrs
Cost of goods sold	`CostOfGoodsSold`	$46.39M	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$149.77M	USD	3 Qtrs
Cost of goods sold	`CostOfGoodsSold`	$29.90M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$74.92M	USD	3 Qtrs
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$57.84M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$14.33M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$141.55M	USD	3 Qtrs
Total expenses	`CostsAndExpenses`	$2.65B	USD	3 Qtrs
Total expenses	`CostsAndExpenses`	$857.32M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$940.75M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$2.75B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$1.54B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$362.80M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$983.74M	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$559.93M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$8.94M	USD	3 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$11.86M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$3.58M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$2.05M	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-4.39M	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-496.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-19.08M	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-6.18M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$4.55M	USD	3 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$-17.04M	USD	3 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$3.08M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$5.68M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$988.29M	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$565.61M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.52B	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$365.88M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$345.88M	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$498.75M	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$177.29M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$101.08M	USD	1 Quarter
Net income	`NetIncomeLoss`	$642.41M	USD	3 Qtrs
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.02B	USD	3 Qtrs
Net income per share - basic	`EarningsPerShareBasic`	$3.64	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$9.66	USD	3 Qtrs
Net income per share - basic	`EarningsPerShareBasic`	$6.14	USD	3 Qtrs
Net income per share - basic	`EarningsPerShareBasic`	$2.53	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$8.84	USD	3 Qtrs
Net income per share - diluted	`EarningsPerShareDiluted`	$2.27	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$3.32	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$5.51	USD	3 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	104.59M	shares	3 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	104.83M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	106.71M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	106.11M	shares	3 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	117.03M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.57M	shares	3 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.99M	shares	3 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.47M	shares	1 Quarter
Net income	`NetIncomeLoss`	$642.41M	USD	3 Qtrs
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.02B	USD	3 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$36.65M	USD	3 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-11.47M	USD	3 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-8.10M	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$21.48M	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$30.00K	USD	3 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$2.00K	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	-	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	-	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$256.70M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$409.80M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.06B	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$630.94M	USD	3 Qtrs

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$642.41M	USD	3 Qtrs
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.02B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$75.84M	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$110.96M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$380.14M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$405.32M	USD	3 Qtrs
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-13.59M	USD	3 Qtrs
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-44.02M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$108.24M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$190.33M	USD	3 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$176.08M	USD	3 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$359.83M	USD	3 Qtrs
Increase in Inventories	`IncreaseDecreaseInInventories`	$235.65M	USD	3 Qtrs
Increase in Inventories	`IncreaseDecreaseInInventories`	$99.71M	USD	3 Qtrs
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-34.86M	USD	3 Qtrs
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$28.21M	USD	3 Qtrs
(Decrease) increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-59.12M	USD	3 Qtrs
(Decrease) increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$282.18M	USD	3 Qtrs
(Decrease) increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-28.91M	USD	3 Qtrs
(Decrease) increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$107.44M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$453.11M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-284.83M	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.10B	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$740.16M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$883.75M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$606.15M	USD	3 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$379.27M	USD	3 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$192.09M	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$361.49M	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$164.96M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-669.44M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-775.55M	USD	3 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$57.00M	USD	3 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$5.08M	USD	3 Qtrs
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$1.85M	USD	3 Qtrs
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$19.93M	USD	3 Qtrs
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$12.65M	USD	3 Qtrs
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	-	USD	3 Qtrs
Payments in connection with deduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	-	USD	3 Qtrs
Payments in connection with deduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$242.12M	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$89.78M	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$226.89M	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$46.95M	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$77.83M	USD	3 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$186.13M	USD	3 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-208.71M	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$256.86M	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$111.26M	USD	3 Qtrs
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$792.07M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$920.36M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$792.07M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$920.36M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.